Aclaris Therapeutics has reported positive Phase 1b clinical results for ATI-052, an investigational bispecific antibody targeting two important inflammatory pathways, demonstrating encouraging improvements in asthma and severe atopic dermatitis. A single dose reduced a key airway inflammation marker by 59% within 15 days in asthma patients, while participants with eczema experienced a 58% mean reduction in disease severity after five weekly doses. The findings provide early clinical evidence supporting simultaneous inhibition of TSLP and IL-4Rα, potentially offering a new approach to managing immune-mediated inflammatory diseases.
The results also demonstrated encouraging short-term tolerability, with no Grade 3 or 4 treatment-emergent adverse events reported across either study. Despite the positive asthma and eczema findings, Aclaris Therapeutics intends to prioritize Phase 2b development of ATI-052 in eosinophilic esophagitis, a chronic inflammatory condition affecting the esophagus. The company is targeting trial initiation in early 2027, although the medicine’s effectiveness in that indication has not yet been established.
How did ATI-052 improve lung function and airway inflammation in the Phase 1b asthma trial?
Aclaris Therapeutics evaluated ATI-052 in a randomized, double-blind, placebo-controlled Phase 1b study involving 16 patients with mild-to-moderate asthma. Eligible participants had baseline fractional exhaled nitric oxide, or FeNO, concentrations of at least 35 parts per billion, indicating elevated type 2 airway inflammation. Patients received a single 480 mg dose of ATI-052 or placebo, with clinical and pharmacodynamic assessments conducted through Day 29.
At Day 15, patients receiving ATI-052 demonstrated a 59% mean reduction in FeNO, equivalent to an absolute decrease of 45 parts per billion, compared with a 15% reduction among placebo recipients. FeNO is a noninvasive biomarker associated with airway inflammation, and reductions can provide evidence that an anti-inflammatory treatment is affecting relevant biological pathways.
Approximately 58% of ATI-052-treated patients achieved FeNO normalization, defined as a concentration of 25 parts per billion or lower, by Day 15. The treatment group also maintained a 40% reduction in FeNO at Day 29, suggesting that biological activity persisted beyond the initial response.
Improvements extended to pulmonary function. Patients receiving ATI-052 experienced a placebo-adjusted mean increase of 200 milliliters in forced expiratory volume in one second, known as FEV1, at Day 15. This measurement assesses how much air a patient can forcibly exhale during the first second and is widely used to evaluate airflow limitation in respiratory disease.
In a post-hoc subgroup analysis involving participants with baseline FEV1 below 80% of predicted normal and reversible airflow obstruction, the mean improvement reached 350 milliliters with ATI-052 compared with a 140-milliliter decline among placebo recipients. Although encouraging, the exploratory subgroup involved very few patients and cannot establish the treatment’s effectiveness in a broader asthma population.
The findings support further investigation of ATI-052’s anti-inflammatory activity, but the short study did not demonstrate reductions in severe asthma exacerbations, hospitalizations or long-term corticosteroid requirements. These outcomes would require larger trials involving patients with more substantial disease burden.
What did the ATI-052 atopic dermatitis study reveal about eczema severity and itching?
The separate Phase 1b atopic dermatitis trial enrolled 14 patients with severe eczema and used a randomized, double-blind, placebo-controlled design. Participants received five weekly doses of ATI-052 at 480 mg or placebo between Weeks 0 and 4, with the primary analysis conducted at Day 57.
Four participants were excluded from the prespecified per-protocol analysis for reasons established before treatment assignments were revealed. Two ATI-052 recipients had incomplete treatment exposure or did not meet eligibility requirements, while two placebo recipients began rescue medication early. These exclusions further reduced the already small population used to assess clinical activity.
Among evaluable participants, ATI-052 produced a 58% mean improvement from baseline in the Eczema Area and Severity Index, compared with a 13% improvement in the placebo group. The resulting placebo-adjusted difference was 45 percentage points, indicating a favorable treatment-associated change in skin disease severity.
The company also reported a 78-percentage-point placebo-adjusted difference in EASI-50 response, an endpoint representing at least a 50% improvement in eczema severity. Response patterns were observed across patients with different baseline disease severity, although the small subgroup sizes limit conclusions about treatment consistency.
Itch relief emerged relatively early, with patients reporting improvement during the first treatment week. At Week 4, ATI-052 produced a 40% placebo-adjusted mean improvement in Peak Pruritus Numerical Rating Scale scores, an established measure of itching severity.
By Day 57, the placebo-adjusted mean improvement in itching reached 43 percentage points. Patients receiving ATI-052 experienced a 38% absolute improvement from baseline, while the placebo group experienced a 5% worsening.
These findings are clinically relevant because persistent itching can disrupt sleep, impair concentration and substantially reduce quality of life in people with severe atopic dermatitis. However, the results remain preliminary, and larger studies are needed to confirm the magnitude, consistency and durability of symptom improvement.
Why could ATI-052’s dual TSLP and IL-4Rα mechanism offer a different inflammatory disease treatment?
ATI-052 is a humanized bispecific antibody designed to inhibit thymic stromal lymphopoietin, commonly known as TSLP, while also blocking the interleukin-4 receptor alpha pathway. This approach targets complementary components of the inflammatory response involved in asthma, eczema and other immune-mediated diseases.
TSLP is an epithelial-derived signaling protein that helps initiate inflammatory responses when barrier tissues encounter environmental triggers. Its activity can contribute to the activation of immune pathways implicated in allergic inflammation, making it an established therapeutic target in respiratory disease.
IL-4Rα participates in signaling involving interleukin-4 and interleukin-13, two cytokines involved in type 2 inflammation. Blocking their shared receptor can reduce inflammatory activity associated with conditions such as atopic dermatitis and certain forms of asthma.
ATI-052 is intended to combine these mechanisms within a single treatment. Aclaris believes that simultaneously targeting upstream TSLP signaling and downstream IL-4/IL-13 activity could produce broader inflammatory suppression than either approach independently.
The company’s pharmacodynamic analysis provided preliminary support for this hypothesis. Among patients with atopic dermatitis receiving ATI-052, investigators observed 95% normalization of the lesional skin proteome at Week 8, meaning the measured immune protein-expression pattern more closely resembled that of unaffected skin.
Additional analyses identified changes across inflammatory pathways involving Th1, Th2 and Th17/Th22 responses, alongside molecular processes associated with tissue remodeling and itching. These findings suggest that ATI-052 may affect several biological mechanisms contributing to inflammatory skin disease.
However, changes in protein expression do not independently establish superior clinical effectiveness. The hypothesis that dual inhibition produces additive or synergistic benefits will require confirmation in larger studies designed to distinguish its effects from those of existing single-target medicines.
How safe was ATI-052 in patients with asthma and severe atopic dermatitis?
Aclaris Therapeutics reported that ATI-052 was generally well tolerated across both Phase 1b studies, with treatment-emergent adverse events predominantly classified as Grade 1. No Grade 3 or Grade 4 treatment-emergent adverse events occurred, and no participants discontinued either study because of adverse events.
Injection-site reactions were uncommon, transient and almost exclusively mild. The company also reported no cases of conjunctivitis, an ocular complication that can occur with certain therapies affecting type 2 inflammatory pathways.
These safety observations are encouraging because immune-targeting treatments may require repeated administration over extended periods. Nevertheless, the combined enrollment of only 30 patients means that uncommon adverse effects cannot be reliably identified.
The limited treatment duration also prevents conclusions about long-term immunological effects, infection risk or tolerability with repeated dosing beyond the current clinical experience. Larger patient populations and longer follow-up will be essential before ATI-052’s benefit-risk profile can be adequately characterized.
Importantly, the absence of conjunctivitis in these studies does not establish that ATI-052 carries a lower ocular risk than approved therapies. Such comparisons would require appropriately designed clinical evidence rather than observations from separate trials.
Why is Aclaris prioritizing eosinophilic esophagitis after positive asthma and eczema results?
Despite demonstrating preliminary activity in both asthma and atopic dermatitis, Aclaris Therapeutics intends to advance ATI-052 initially into Phase 2b testing for eosinophilic esophagitis, commonly abbreviated as EoE.
Eosinophilic esophagitis is a chronic immune-mediated condition characterized by inflammation of the esophagus, often leading to difficulty swallowing, food impaction and persistent feeding-related symptoms. Type 2 inflammatory signaling plays an important role in the disorder, creating a biological rationale for investigating treatments targeting IL-4Rα and related pathways.
Aclaris believes ATI-052’s dual mechanism could potentially address several inflammatory processes contributing to eosinophilic esophagitis. However, the asthma and eczema findings do not establish that the antibody will be effective in patients with esophageal inflammation.
Chief executive officer Neal Walker indicated that the company considers the Phase 1b results supportive of ATI-052’s broader therapeutic potential while maintaining a focused development strategy. Management intends to initiate the eosinophilic esophagitis study in early 2027 and provide additional information about another potential indication.
The treatment has also been engineered for an extended half-life, with earlier Phase 1a findings suggesting an estimated duration of approximately 45 days. This property could potentially support dosing intervals of up to three months, although the optimal schedule remains to be established in patient studies.
For asthma and atopic dermatitis, ATI-052’s initial performance provides encouraging evidence of biological and symptomatic activity. However, the company has not committed to immediate late-stage development in either condition, making further regulatory and clinical planning necessary before its potential role can be assessed.
The next important milestone will be initiation of the planned Phase 2b eosinophilic esophagitis study, alongside continued analysis of longer-term responses from the existing trials. Larger controlled investigations will determine whether ATI-052’s dual-targeting approach can produce clinically meaningful, durable benefits with an acceptable safety profile. For now, ATI-052 remains an investigational antibody showing promising early results across two inflammatory diseases, but its clinical advantages over approved treatments and its potential role in eosinophilic esophagitis have yet to be demonstrated.
